Avior Pharmaceuticals

Avior Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing innovative therapies for chronic pruritus and other symptoms associated with liver and kidney diseases. The company utilizes a proprietary transmucosal film delivery platform to improve the efficacy and safety profiles of established drugs. Its lead candidate, AV104, is a nalmefene-based film designed to treat itching in patients with Primary Biliary Cholangitis (PBC). By leveraging the 505(b)(2) regulatory pathway, Avior aims to bring treatments to market more efficiently than traditional drug development routes. The company is headquartered in Cary, North Carolina, and is led by a team of experienced pharmaceutical executives.